Switch to:
More From Other Websites
How Roche’s Rituxan and Acterma Are Positioned after 1H17 Sep 22 2017
How Is Novartis’s Subsidiary Sandoz Positioned after 1H17? Sep 22 2017
Ocrevus Expected to Significantly Drive Roche’s Revenue Growth Sep 22 2017
Cancer Space Update: Mixed Week for Pfizer, Roche Falters Sep 22 2017
Alecensa Could Boost Roche’s Long-Term Revenue Growth Sep 22 2017
Yestar Healthcare Holdings Company Limited -- Moody's: Yestar's acquisition of IVD distributor in... Sep 22 2017
Esbriet Could Boost Roche’s Revenue Growth in 2H17 Sep 21 2017
Could Tecentriq Be Roche’s Long-Term Growth Driver? Sep 21 2017
Roche’s Tecentriq Witnessed High Revenue Growth in 1H17 Sep 21 2017
Biogen: Buy or Hold? Sep 21 2017
How is the Age-Related Macular Degeneration Space Faring Now? Sep 21 2017
Roche (RHHBY) Announces Positive Data on Leukemia Drug Sep 19 2017
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA Sep 18 2017
Phase III Data Showed That Venclexta Plus Rituxan Helped People With Previously Treated Chronic... Sep 18 2017
FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy Sep 18 2017
FDA Approves First 'Biosimilar' for Cancer Treatment Sep 15 2017
Amgen/Allergan's Avastin Biosimilar Secures FDA Approval Sep 15 2017
The Latest on TEVA’s Oncology Business Sep 15 2017
This Small Cap Biotech Soars On Deals With Bristol-Myers, Roche Sep 14 2017
Amgen and Allergan say FDA has approved biosimilar of Roche's Avastin Sep 14 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK